Journal of Clinical Epidemiology
Volume 63, Issue 10 , Pages 1132-1144 , October 2010

The quality of eight health status measures were compared for chronic opioid dependence

  • Bohdan Nosyk

      Affiliations

    • Centre for Health Evaluation and Outcome Sciences, British Columbia, Canada
    • ,
  • Huiyung Sun

      Affiliations

    • Centre for Health Evaluation and Outcome Sciences, British Columbia, Canada
    • ,
  • Daphne P. Guh

      Affiliations

    • Centre for Health Evaluation and Outcome Sciences, British Columbia, Canada
    • ,
  • Eugenia Oviedo-Joekes

      Affiliations

    • Centre for Health Evaluation and Outcome Sciences, British Columbia, Canada
    • ,
  • David C. Marsh

      Affiliations

    • Centre for Health Evaluation and Outcome Sciences, British Columbia, Canada
    • School of Population and Public Health, University of British Columbia, British Columbia, Canada
    • Vancouver Coastal Health Authority, British Columbia, Canada
    • Centre for Addictions Research BC, British Columbia, Canada
    • ,
  • Suzanne Brissette

      Affiliations

    • Centre de recherche du l'Université de Montreal, Quebec, Canada
    • ,
  • Martin T. Schechter

      Affiliations

    • Centre for Health Evaluation and Outcome Sciences, British Columbia, Canada
    • School of Population and Public Health, University of British Columbia, British Columbia, Canada
    • ,
  • Aslam H. Anis

      Affiliations

    • Centre for Health Evaluation and Outcome Sciences, British Columbia, Canada
    • School of Population and Public Health, University of British Columbia, British Columbia, Canada
    • Corresponding Author InformationCorresponding author. Centre for Health Evaluation & Outcome Sciences, St. Paul's Hospital, 620B-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada. Tel.: +604-806-8692; fax: +604-806-8778.

References 

  1. Mason BJ, Kocsis JH, Melia D, Khuri ET, Sweeney J, Wells A, et al. Psychiatric comorbidity in methadone maintained patients. J Addict Dis. 1998;17:75–89
  2. Lelutiu-Weinberger C, Pouget ER, Des Jarlais DD, Cooper HL, Scheinmann R, Stern R, et al. A meta-analysis of the hepatitis C virus distribution in diverse racial/ethnic drug injector groups. Soc Sci Med. 2009;68:579–590
  3. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. 2007 Reference Group to the UN on HIV and Injecting Drug Use Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372:1733–1745
  4. McLellan AT, Cacciola JC, Alterman AI, Rikoon SH, Carise D. The Addiction Severity Index at 25: origins, contributions and transitions. Am J Addict. 2006;15:113–124
  5. Puigdollers E, Domingo-Salvany A, Brugal MT, Torrens M, Alvaro J, Castillo C, et al. Characteristics of heroin addicts entering methadone maintenance treatment: quality of life and gender. Subst Use Misuse. 2004;39:1353–1368
  6. Kirschner B, Guyatt G. A methodological framework for assessing health indices. J Chronic Dis. 1985;38:27–36
  7. Terwee CB, Bot SDM, de Boer MR, van der Windt DAWM, Knol DL, Dekker J, et al. Quality criteria were proposed for measurement properties of heath status questionnaires. J Clin Epidemiol. 2007;60:34–42
  8. Makela K. Studies of the reliability and validity of the addiction severity index. Addiction. 2004;99:398–410discussion 411–8
  9. Oviedo-Joekes E, Nosyk B, Marsh DC, Guh D, Brissette S, Gartry C, et al. Scientific and political challenges in North America's first randomized controlled trial of heroin-assisted treatment for severe heroin addiction: rationale and design of the NAOMI study. Clin Trials. 2009;6:261–271
  10. Oviedo-Joekes E, Nosyk B, Brissette S, Chettiar J, Schneeberger P, Marsh DC, et al. The North American Opiate Medication Initiative (NAOMI): profile of participants in North America's first trial of heroin-assisted treatment. J Urban Health. 2008;85:812–825
  11. Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, et al. A randomized trial of diacetylmorphine vs. methadone for treatment-refractory opioid addiction. N Engl J Med. 2009;361:777–786
  12. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, et al. The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9:199–213
  13. Calsyn DA, Saxon AJ, Bush KR, Howell DN, Baer JS, Sloan KL, et al. The addiction severity index medical and psychiatric composite scores measure similar domains as the SF-36 in substance-dependent veterans: concurrent and discriminant validity. Drug Alcohol Depend. 2004;76:165–171
  14. Darke S, Hall W, Wodak A, Heather N, Ward J. Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. Br J Addict. 1992;87:733–742
  15. Marsden J, Gossop G, Stewart D, Best D, Farrell M, Lehmann P, et al. The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome. Addiction. 1998;93:1857–1867
  16. Home page for the World Health Organization Disability Assessment Schedule II (WHODAS II). Available at http://www.who.int/icidh/whodas/index.html2001;(accessed September 2006)
  17. World Health Organization . International classification of functioning, disability and health (ICF). Geneva, Switzerland: World Health Organization; 2001;
  18. Hudson M, Steele R, Taillefer S, Baron M Canadian Scleroderma Research Group. Quality of life in systemic sclerosis: psychometric properties of the World Health Organization Disability Assessment Schedule II. Arthritis Rheum. 2008;59:270–278
  19. Pösl M, Cieza A, Stucki G. Psychometric properties of the WHODASII in rehabilitation patients. Qual Life Res. 2007;16:1521–1531
  20. Chisolm TH, Abrams HB, McArdle R, Wilson RH, Doyle PJ. The WHO-DAS II: psychometric properties in the measurement of functional health status in adults with acquired hearing loss. Trends Amplif. 2005;9:111–126
  21. Euroqol Group . Euroqol—a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208
  22. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53–72
  23. Coons SJ, Rao S, Keininger DL, Hays RD. A comparative review of generic quality-of-life instruments. Pharmacoeconomics. 2000;17:13–35
  24. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43:203–220
  25. Van der Zanden BP, Dijkgraaf MGW, Blanken P, de Borgie CAJM, van Ree JM, van den Brink W. Validity of the EQ-5D as a generic health outcome instrument in a heroin-dependent population. Drug Alcohol Depend. 2006;82:111–118
  26. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21:271–292
  27. Ware JE, Sherbourne D. The MOS 36-item short form health survey (SF-36). 1. Conceptual framework and item selection. Med Care. 1992;30:473–483
  28. Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ. 2004;13:873–884
  29. Guyatt GH, Kirshner B, Jaeschke R. Measuring health status: what are the necessary measurement properties?. J Clin Epidemiol. 1992;45:1341–1345
  30. Lai JS, Crane PK, Cella D. Factor analysis for assessing sufficient unidimensionality of cancer related fatigue. Qual Life Res. 2006;15:1179–1190
  31. O'Connor BP. SPSS and SAS programs for determining the number of components using parallel analysis and Velicer's MAP test. Behav Res Meth Instrum Comput. 2000;32:396–402
  32. Streiner DL, Norman GR. Health measurement scales. A practical guide to their development and use. New York, NY: Oxford University Press; 2003;
  33. Verhaak PFM, Heijmans MJWM, Peters L, Rijken M. Chronic disease and mental disorder. Soc Sci Med. 2005;60:789–797
  34. Gonen M. Analyzing receiver operating characteristic curves with SAS. Cary, NC: SAS Press Series; 2007;
  35. Guyatt GH, Deyo RA, Charlson M, Levine MN, Mitchell A. Responsiveness and validity in health status measurement: a clarification. J Clin Epidemiol. 1989;42:403–408
  36. Hays RD, Hadorn D. Responsiveness to change: an aspect of validity, not a separate dimension. Qual Life Res. 1992;1:73–75
  37. Krabbe PFM, Peerenboom L, Langenhoff BS, Ruers TJM. Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30. Qual Life Res. 2004;13:1247–1253
  38. Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61:102–109
  39. Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat. 2005;28:321–329
  40. Kokkevi A, Hartgers C. EuropASI: European adaptation of a multidimensional assessment instrument for drug and alcohol dependence. Eur Addict Res. 1995;1:208–210
  41. Husted JA, Cook RJ, Farewell VT, Gladman DD. Methods for assessing responsiveness: a critical review and recommendations. J Clin Epidemiol. 2000;53:459–468
  42. In:  Brooks R,  Robin R,  de Charro F editor. The Measurement and Valuation of Health Status Using EQ-5D: a European Perspective (Evidence From the Euroqol BIOMED Research Programme. The Netherlands: Kluwer Academic Publishers; 2003;
  43. Conner-Spady B, Suarez-Almazor E. Variation in the estimation of quality-adjusted life years by different preference-based instruments. Med Care. 2004;41:791–801
  44. Hollingsworth W, Mackenzie R, Todd CJ, Dixon AK. Measuring changes in quality of life following magnetic resonance imaging of the knee: SF-36, EuroQol, or Rosser Index. Qual Life Res. 1995;4:325–334
  45. Essink-Bot ML, Krabbe PFM, Bonsel GJ, Aaronson NK. An empirical comparison of four generic health status measures: the Nottingham Health Profile, the medical outcomes study 36-item Short Form Health Survey, the COOP/WONCA charts and the EuroQol instrument. Med Care. 1997;35:522–537
  46. Jenkinson C, Stradling J, Petersen S. How should we evaluate health status? A comparison of three methods in patients presenting with obstructive sleep apnoea. Qual Life Res. 1998;7:95–100
  47. Longworth L, Bryan S. An empirical comparison of the EQ-5D and SF-6D in liver transplant patients. Health Econ. 2003;12:1061–1067
  48. Marra CA, Rashidi AA, Guh D, Kopec JA, Abrahamowicz M, Esdaile JM, et al. Are indirect utility measures reliable and responsive in rheumatoid arthritis patients?. Qual Life Res. 2005;14:1333–1344
  49. Nosyk B, MacNab YC, Sun H, Marsh DC, Fischer B, Schechter MT, et al. Proportional hazards frailty models for recurrent methadone maintenance treatment. Am J Epidemiol. 2009;170:783–792

 Source of support: The North American Opiate Medication Initiative was supported by a Canadian Institutes of Health Research operating grant.

PII: S0895-4356(09)00388-6

doi: 10.1016/j.jclinepi.2009.12.003

Journal of Clinical Epidemiology
Volume 63, Issue 10 , Pages 1132-1144 , October 2010

Article Tools